The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Partial Thromboplastin Time

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Partial Thromboplastin Time


Psychiatry related information on Partial Thromboplastin Time

  • The association between plasma fibrinogen, factor VII, factor X, activated partial thromboplastin time, antithrombin III and the lifestyle factors cigarette smoking, alcohol use, fat intake and physical activity was assessed in 802 men aged 70-90 years in Zutphen (The Netherlands), Montegiorgio and Crevalcore (Italy) [6].

High impact information on Partial Thromboplastin Time


Chemical compound and disease context of Partial Thromboplastin Time


Biological context of Partial Thromboplastin Time


Anatomical context of Partial Thromboplastin Time


Associations of Partial Thromboplastin Time with chemical compounds


Gene context of Partial Thromboplastin Time


Analytical, diagnostic and therapeutic context of Partial Thromboplastin Time


  1. Obstetric complications associated with the lupus anticoagulant. Branch, D.W., Scott, J.R., Kochenour, N.K., Hershgold, E. N. Engl. J. Med. (1985) [Pubmed]
  2. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. Koopman, M.M., Prandoni, P., Piovella, F., Ockelford, P.A., Brandjes, D.P., van der Meer, J., Gallus, A.S., Simonneau, G., Chesterman, C.H., Prins, M.H. N. Engl. J. Med. (1996) [Pubmed]
  3. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. Ahmed, T., Garrigo, J., Danta, I. N. Engl. J. Med. (1993) [Pubmed]
  4. How well does the activated partial thromboplastin time predict postoperative hemorrhage? Suchman, A.L., Mushlin, A.I. JAMA (1986) [Pubmed]
  5. Lupus anticoagulant in the acquired immunodeficiency syndrome. Bloom, E.J., Abrams, D.I., Rodgers, G. JAMA (1986) [Pubmed]
  6. Haemostatic parameters and lifestyle factors in elderly men in Italy and The Netherlands. Bijnen, F.C., Feskens, E.J., Giampaoli, S., Menotti, A., Fidanza, F., Hornstra, G., Caspersen, C.J., Mosterd, W.L., Kromhout, D. Thromb. Haemost. (1996) [Pubmed]
  7. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. Nagashima, M., Yin, Z.F., Zhao, L., White, K., Zhu, Y., Lasky, N., Halks-Miller, M., Broze, G.J., Fay, W.P., Morser, J. J. Clin. Invest. (2002) [Pubmed]
  8. Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E. A preliminary report. Sinclair, S.B., Greig, P.D., Blendis, L.M., Abecassis, M., Roberts, E.A., Phillips, M.J., Cameron, R., Levy, G.A. J. Clin. Invest. (1989) [Pubmed]
  9. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. Colman, R.W., Bagdasarian, A., Talamo, R.C., Scott, C.F., Seavey, M., Guimaraes, J.A., Pierce, J.V., Kaplan, A.P. J. Clin. Invest. (1975) [Pubmed]
  10. Frequency of inherited bleeding disorders in women with menorrhagia. Kadir, R.A., Economides, D.L., Sabin, C.A., Owens, D., Lee, C.A. Lancet (1998) [Pubmed]
  11. Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. Gurney, H.P., Ackland, S., Gebski, V., Farrell, G. J. Clin. Oncol. (1998) [Pubmed]
  12. Factors related to early mortality after transjugular intrahepatic portosystemic shunt for failed endoscopic therapy in acute variceal bleeding. Patch, D., Nikolopoulou, V., McCormick, A., Dick, R., Armonis, A., Wannamethee, G., Burroughs, A. J. Hepatol. (1998) [Pubmed]
  13. Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model. Imura, Y., Stassen, J.M., Collen, D. J. Pharmacol. Exp. Ther. (1992) [Pubmed]
  14. Development of a novel mouse model for dengue virus infection. An, J., Kimura-Kuroda, J., Hirabayashi, Y., Yasui, K. Virology (1999) [Pubmed]
  15. Multivariate regression modeling for the prediction of inflammation, systemic pressure, and end-organ function in severe sepsis. Slotman, G.J., Quinn, J.V. Shock (1997) [Pubmed]
  16. Shortening of bleeding time by 1-deamino-8-D-arginine vasopressin in various bleeding disorders. Kobrinsky, N.L., Israels, E.D., Gerrard, J.M., Cheang, M.S., Watson, C.M., Bishop, A.J., Schroeder, M.L. Lancet (1984) [Pubmed]
  17. Combined administration of aspirin and a specific thrombin inhibitor in man. Clarke, R.J., Mayo, G., FitzGerald, G.A., Fitzgerald, D.J. Circulation (1991) [Pubmed]
  18. Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator. Gimple, L.W., Gold, H.K., Leinbach, R.C., Coller, B.S., Werner, W., Yasuda, T., Johns, J.A., Ziskind, A.A., Finkelstein, D., Collen, D. Circulation (1989) [Pubmed]
  19. A unique precipitating autoantibody against plasma thromboplastin antecedent associated with multiple apparent plasma clotting factor deficiencies in a patient with systemic lupus erythematosus. Poon, M.C., Saito, H., Koopman, W.J. Blood (1984) [Pubmed]
  20. Prognostic value of clotting and fibrinolytic systems in a follow-up of 165 liver cirrhotic patients. CALC Group. Violi, F., Ferro, D., Basili, S., Cimminiello, C., Saliola, M., Vezza, E., Cordova, C. Hepatology (1995) [Pubmed]
  21. Platelet factor 4 efficiently reverses heparin anticoagulation in the rat without adverse effects of heparin-protamine complexes. Cook, J.J., Niewiarowski, S., Yan, Z., Schaffer, L., Lu, W., Stewart, G.J., Mosser, D.M., Myers, J.A., Maione, T.E. Circulation (1992) [Pubmed]
  22. Neutralization of heparin activity by neutrophil lactoferrin. Wu, H.F., Lundblad, R.L., Church, F.C. Blood (1995) [Pubmed]
  23. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Attal, M., Huguet, F., Rubie, H., Huynh, A., Charlet, J.P., Payen, J.L., Voigt, J.J., Brousset, P., Selves, J., Muller, C. Blood (1992) [Pubmed]
  24. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Chiu, H.M., Hirsh, J., Yung, W.L., Regoeczi, E., Gent, M. Blood (1977) [Pubmed]
  25. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators. Hsia, J., Kleiman, N., Aguirre, F., Chaitman, B.R., Roberts, R., Ross, A.M. J. Am. Coll. Cardiol. (1992) [Pubmed]
  26. Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. Leyvraz, P.F., Richard, J., Bachmann, F., Van Melle, G., Treyvaud, J.M., Livio, J.J., Candardjis, G. N. Engl. J. Med. (1983) [Pubmed]
  27. Partial purification and characterization of contact activation cofactor. Schiffman, S., Lee, P. J. Clin. Invest. (1975) [Pubmed]
  28. Immunologic and coagulation disorders in chlorpromazine-treated patients. Zarrabi, M.H., Zucker, S., Miller, F., Derman, R.M., Romano, G.S., Hartnett, J.A., Varma, A.O. Ann. Intern. Med. (1979) [Pubmed]
  29. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Jang, I.K., Gold, H.K., Ziskind, A.A., Leinbach, R.C., Fallon, J.T., Collen, D. Circulation (1990) [Pubmed]
  30. Neutralization of low molecular weight heparin by polybrene prevents thromboxane release and severe pulmonary hypertension in awake sheep. Montalescot, G., Zapol, W.M., Carvalho, A., Robinson, D.R., Torres, A., Lowenstein, E. Circulation (1990) [Pubmed]
  31. Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit. Day, K.C., Hoffman, L.C., Palmier, M.O., Kretzmer, K.K., Huang, M.D., Pyla, E.Y., Spokas, E., Broze, G.J., Warren, T.G., Wun, T.C. Blood (1990) [Pubmed]
  32. Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Slungaard, A., Fernandez, J.A., Griffin, J.H., Key, N.S., Long, J.R., Piegors, D.J., Lentz, S.R. Blood (2003) [Pubmed]
  33. "ProC Global": a functional screening test that predicts recurrent venous thromboembolism. Grand'Maison, A., Bates, S.M., Johnston, M., McRae, S., Ginsberg, J.S. Thromb. Haemost. (2005) [Pubmed]
  34. Pharmacokinetics of saruplase, a recombinant unglycosylated human single-chain urokinase-type plasminogen activator and its effects on fibrinolytic and haemostatic parameters in healthy male subjects. de Boer, A., Kluft, C., Gerloff, J., Dooijewaard, G., Günzler, W.A., Beier, H., van der Meer, F.J., Cohen, A.F. Thromb. Haemost. (1993) [Pubmed]
  35. Improved distinction of factor V wild-type and factor V Leiden using a novel prothrombin-based activated protein C resistance assay. Wilmer, M., Stocker, C., Bühler, B., Conell, B., Calatzis, A. Am. J. Clin. Pathol. (2004) [Pubmed]
  36. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. Blank, M., Krause, I., Fridkin, M., Keller, N., Kopolovic, J., Goldberg, I., Tobar, A., Shoenfeld, Y. J. Clin. Invest. (2002) [Pubmed]
  37. Lupus-like anticoagulants and lower extremity arterial occlusive disease. Eldrup-Jorgensen, J., Brace, L., Flanigan, D.P., Schwarcz, T.H., Fritsma, G., Meyer, J.P., Schuler, J.J. Circulation (1989) [Pubmed]
  38. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Antman, E.M. Circulation (1994) [Pubmed]
  39. Guidelines for management of left-sided prosthetic valve thrombosis: a role for thrombolytic therapy. Consensus Conference on Prosthetic Valve Thrombosis. Lengyel, M., Fuster, V., Keltai, M., Roudaut, R., Schulte, H.D., Seward, J.B., Chesebro, J.H., Turpie, A.G. J. Am. Coll. Cardiol. (1997) [Pubmed]
  40. Outcome after proctectomy for rectal cancer in Department of Veterans Affairs Hospitals: a report from the National Surgical Quality Improvement Program. Longo, W.E., Virgo, K.S., Johnson, F.E., Wade, T.P., Vernava, A.M., Phelan, M.A., Henderson, W.G., Daley, J., Khuri, S.F. Ann. Surg. (1998) [Pubmed]
WikiGenes - Universities